MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells

Area of Science:

• Molecular Biology
• Cancer Research
• Pharmacology

Background:

• Histone deacetylases (HDACs) regulate gene expression via chromatin remodeling by controlling histone acetylation status.
• HDACs are implicated in cancer development, making them potential targets for pharmacological intervention.
• Inappropriate recruitment of HDACs can lead to gene repression, suggesting a role in cancer progression.

Purpose of the Study:

• To investigate the hypothesis that HDAC inhibitors potentiate the anti-cancer effects of 5-fluorouracil (5-FU) in colorectal cancer (CRC).
• To evaluate the synergistic interaction between specific HDAC inhibitors (SBHA, MS275) and 5-FU on CRC cell survival in vitro.

Main Methods:

• In vitro experiments utilizing colorectal cancer (CRC) cell lines.
• Treatment with histone deacetylase (HDAC) inhibitors SBHA and MS275, alone and in combination with 5-fluorouracil (5-FU).
• Assessment of cell survival and apoptotic signals.

Main Results:

• HDAC inhibitors SBHA and MS275 demonstrated a potent synergistic interaction with 5-FU against colorectal cancer cells.
• The combination therapy resulted in a significant reduction in cytotoxic doses required for efficacy.
• The observed synergism is likely due to an augmented apoptotic signal.

Conclusions:

• HDAC inhibitors exhibit significant synergistic effects when combined with 5-FU in colorectal cancer treatment models.
• This combination strategy offers a promising approach to enhance therapeutic efficacy and reduce toxicity in colorectal cancer therapy.
• Targeting HDACs alongside conventional chemotherapy represents a viable strategy for improving patient outcomes.